|
HSF2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
4.6100000483662E-09 |
| Normal-vs-Stage3 |
1.26965105096133E-12 |
| Normal-vs-Stage4 |
2.49744669389429E-12 |
| Stage1-vs-Stage2 |
7.864000E-01 |
| Stage1-vs-Stage3 |
9.468600E-01 |
| Stage1-vs-Stage4 |
2.488600E-01 |
| Stage2-vs-Stage3 |
8.535000E-01 |
| Stage2-vs-Stage4 |
6.250200E-01 |
| Stage3-vs-Stage4 |
3.729600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.396810E-04 |
| Normal-vs-Asian |
7.43920036683221E-10 |
| Caucasian-vs-AfricanAmerican |
9.978300E-02 |
| Caucasian-vs-Asian |
9.415400E-01 |
| AfricanAmerican-vs-Asian |
1.661620E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.24265050974282E-14 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
8.741600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62492241884138E-12 |
| Normal-vs-Age(41-60Yrs) |
8.77076189453874E-15 |
| Normal-vs-Age(61-80Yrs) |
3.63453711571537E-12 |
| Normal-vs-Age(81-100Yrs) |
3.342200E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.636000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.349000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.342600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.652800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.584600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.964000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.158600E-01 |
| Classical-VS-Follicular |
2.847600E-01 |
| Classical-VS-Other |
8.068600E-01 |
| Classical-VS-Normal |
1.35769950837528E-10 |
| Tall-VS-Follicular |
9.796600E-01 |
| Tall-VS-Other |
8.543600E-01 |
| Tall-VS-Normal |
6.5626004630559E-10 |
| Follicular-VS-Other |
8.853400E-01 |
| Follicular-VS-Normal |
3.81059628296043E-11 |
| Other-VS-Normal |
3.120400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
1.65645275274073E-12 |
| N0-vs-N1 |
4.765400E-01 |
|
|
